Neurocrine Biosciences, Inc. (NBIX) Director Sells $855,000.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $90.00, for a total value of $855,000.00. Following the completion of the sale, the director now directly owns 34,250 shares of the company’s stock, valued at approximately $3,082,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $82.17 on Tuesday. Neurocrine Biosciences, Inc. has a 1-year low of $39.21 and a 1-year high of $91.82. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $7,270.00, a PE ratio of -37.01, a price-to-earnings-growth ratio of 13.14 and a beta of 0.26.

A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. Legal & General Group Plc raised its holdings in Neurocrine Biosciences by 8.7% during the second quarter. Legal & General Group Plc now owns 31,859 shares of the company’s stock valued at $1,465,000 after buying an additional 2,554 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Neurocrine Biosciences by 2.3% during the second quarter. Principal Financial Group Inc. now owns 77,679 shares of the company’s stock valued at $3,574,000 after buying an additional 1,728 shares in the last quarter. Teachers Advisors LLC raised its holdings in Neurocrine Biosciences by 10.8% during the second quarter. Teachers Advisors LLC now owns 91,550 shares of the company’s stock valued at $4,211,000 after buying an additional 8,903 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in Neurocrine Biosciences by 21.1% during the second quarter. TIAA CREF Investment Management LLC now owns 329,035 shares of the company’s stock valued at $15,136,000 after buying an additional 57,371 shares in the last quarter. Finally, Amalgamated Bank raised its holdings in Neurocrine Biosciences by 28.7% during the second quarter. Amalgamated Bank now owns 16,151 shares of the company’s stock valued at $743,000 after buying an additional 3,602 shares in the last quarter.

A number of analysts recently issued reports on NBIX shares. Jefferies Group lifted their price objective on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $85.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and set a $83.00 price objective (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $84.13.

COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/insider-selling-neurocrine-biosciences-inc-nbix-director-sells-855000-00-in-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply